Equillium Q2 2023 net loss narrows to $3.3M; cash $48.4M; stock repurchase authorized

Equillium, Inc.

2023-Q2 EPS reported -$0.21 revenue$18,003,000

Revenue of $9.1M from Ono partnership; net loss $0.10/sh vs $0.41/sh loss year ago.
Cash and investments $48.4M at June 30; fully prepaid and retired debt facility.
Authorized $7.5M stock repurchase program; cash runway expected into 2025.
Promoted Dr. Maple Fung to Chief Medical Officer; EQ101 alopecia areata data due 2H 2023.
Ono option for itolizumab could bring ~$35M; EQUALISE lupus nephritis topline early 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.